Peer-reviewed veterinary case report
Sacubitril/valsartan effects in dogs with heart enlargement
By Newhard, Daniel K. et al.·Published in Journal of Veterinary Internal Medicine·2018·College of Veterinary Medicine, Auburn University Department of Clinical Sciences, , Auburn, Alabama·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
- Species:
- dog
Plain-English summary
A group of 13 small dogs with heart enlargement due to myxomatous mitral valve disease (a common heart condition in dogs) were given either a new medication called sacubitril/valsartan or a placebo to see how it affected their heart health. After 30 days, the dogs that received the medication showed a significantly lower increase in a hormone related to heart stress compared to those on the placebo. However, there were no major differences in other heart tests or any side effects noted in either group. This suggests that sacubitril/valsartan could be a promising treatment option for dogs with this heart condition.
People also search for: dog heart disease treatment · sacubitril valsartan for dogs · myxomatous mitral valve disease in dogs
Abstract
Abstract Background The effects of sacubitril/valsartan (S/V) on the renin-angiotensin-aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown. Objectives To determine the pharmacodynamic effects of S/V on the RAAS, natriuretic peptide concentrations, systolic arterial pressure (SAP), tests of renal function, and serum electrolyte concentrations in dogs with cardiomegaly secondary to MMVD. Animals Thirteen client-owned dogs weighing 4-15 kg with American College of Veterinary Internal Medicine (ACVIM) Stage B2 MMVD. Methods Prospective, randomized, double-blind, placebo-controlled pilot study of S/V in dogs with ACVIM Stage B2 MMVD. Results Thirteen dogs were recruited: S/V (n = 7) and placebo (n = 6). The median percentage increase in urinary aldosterone to creatinine ratio (UAldo : C) between day 0 and day 30 was significantly lower in the S/V group (12%; P = .032) as compared with the placebo group (195%). The median percentage decrease of NT-proBNP concentration from day 0 to day 30 was not statistically different between groups (P = .68). No statistical differences were seen in echocardiographic, thoracic radiographic, SAP, or serum biochemical test results measured at any time point between groups. No adverse events were observed for dogs in either group. Conclusion and Clinical Importance Sacubitril/valsartan may provide a new pharmaceutical method to effectively inhibit the RAAS in dogs with ACVIM Stage B2 MMVD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/jvim.15240